---
title: "Contineum Therapeutics updates corporate presentation; highlights PIPE-791 progress, cash runway through mid-2029"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292528102.md"
description: "Contineum Therapeutics updated its corporate presentation, highlighting PIPE-791 as the lead program with ongoing Phase 2 trials for IPF and favorable Phase 1 safety data. The company also detailed the PIPE-307 partnership with Janssen. Additionally, Contineum projects its cash runway extends through mid-2029, reflecting disciplined capital allocation."
datetime: "2026-07-13T20:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292528102.md)
  - [en](https://longbridge.com/en/news/292528102.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292528102.md)
---

# Contineum Therapeutics updates corporate presentation; highlights PIPE-791 progress, cash runway through mid-2029

**Contineum Therapeutics updated its corporate presentation to highlight PIPE-791 clinical progress, PIPE-307 partnership details and a projected cash runway through mid-2029.**

**Key Highlights:**

-   Updated corporate presentation (Exhibit 99.1) posted to company website; future updates will be posted online, not via 8-K filings.
-   PIPE-791 presented as lead program: brain-penetrant LPAR1 antagonist with Phase 2 global IPF trial underway; estimated completion June 2028.
-   PIPE-791 shows favorable Phase 1 safety, \>90% receptor occupancy at low doses and positive Phase 1B chronic pain signals, supporting further development.
-   PIPE-307 (JNJ-5120) M1R antagonist developed by Janssen; Janssen retains sole discretion to develop for MDD or other indications.
-   Presentation notes disciplined capital allocation and projects existing cash and equivalents to fund operations through mid-2029.

Original SEC Filing: Contineum Therapeutics, Inc. \[ CTNM \] - 8-K - Jul. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CTNM.US](https://longbridge.com/en/quote/CTNM.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [BMS bags first FDA approval for CELMoD franchise with Zenbexus](https://longbridge.com/en/news/295947034.md)
- [Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference](https://longbridge.com/en/news/279135975.md)
- [Bioxytran reports functional gains in first CIDP patient treated with PLICID galectin antagonist](https://longbridge.com/en/news/295525258.md)
- [Idorsia says DEA proposes moving dual orexin insomnia drugs to Schedule V](https://longbridge.com/en/news/295485874.md)
- [MapLight Therapeutics prices USD 150 million PIPE at USD 11.38 a share](https://longbridge.com/en/news/295804908.md)